9 Lab Tests That Reveal Insulin Resistance in Menopause Before It Becomes Type 2 Diabetes
The frustrating thing about this particular corner of menopause is how invisible it feels until it isn't. Weight shifting to the middle, energy crashing after meals, craving sugar at 3pm — these are real signals the body is sending, and most women are never told they might be metabolic ones. Getting the right labs doesn't mean bracing for bad news; it means finally having something concrete to work with.
Learn more about Rose →Fasting Insulin (the test most doctors skip)
Fasting glucose can sit in the normal range for years while fasting insulin quietly climbs — because the pancreas is compensating by pumping out more insulin just to keep blood sugar stable. A fasting insulin above 10 µIU/mL is a meaningful early warning sign even when glucose looks fine. This is one of the most informative single tests a menopausal woman can request, and it is rarely ordered on standard panels without specifically asking for it.
HOMA-IR (calculated from fasting glucose and insulin together)
HOMA-IR — Homeostatic Model Assessment of Insulin Resistance — is not a blood draw itself but a calculation using fasting insulin and fasting glucose together, making it far more revealing than either number alone. A score above 1.9 suggests early insulin resistance; above 2.9 indicates more significant resistance in most reference ranges used by metabolic researchers. Because estrogen loss impairs insulin sensitivity directly, HOMA-IR tends to worsen in the perimenopause years even in women who have not changed their diet or weight.
HbA1c (but interpreted with important caveats)
HbA1c measures the percentage of hemoglobin that has been glycated over approximately three months, giving a longer view of blood sugar patterns than a single fasting draw. In menopausal women, HbA1c between 5.7% and 6.4% signals prediabetes — a window where lifestyle and hormonal interventions are highly effective — but the test can underestimate true blood sugar exposure in women with iron deficiency anemia, which is common in perimenopause. Interpreting HbA1c alongside iron studies is worth discussing with a clinician for this reason.
Fasting Glucose (useful, but not the full picture)
Fasting glucose remains a foundational marker and should absolutely be included, but its limitation is that it only reflects blood sugar status after an overnight fast — the easiest time for a compensating metabolic system to look normal. Values between 100–125 mg/dL classify as impaired fasting glucose and warrant closer investigation rather than reassurance. The critical point for menopausal women is that fasting glucose alone, without fasting insulin, tells only half the story.
Two-Hour Glucose Tolerance Test (the stress test for metabolism)
The oral glucose tolerance test (OGTT) involves drinking a measured glucose solution and measuring blood sugar response at one and two hours, revealing how the body handles a real glucose load rather than its resting baseline. A two-hour value between 140–199 mg/dL indicates impaired glucose tolerance — a stage that fasting tests frequently miss entirely. Research consistently shows that post-meal glucose excursions are often the first metabolic abnormality to appear in perimenopausal women, making this test particularly valuable in this life stage.
Triglycerides (the underappreciated metabolic canary)
Elevated fasting triglycerides are one of the most reliable early indicators of insulin resistance, because when cells stop responding well to insulin, the liver compensates by converting excess glucose into triglycerides and releasing them into the bloodstream. A fasting triglyceride level above 150 mg/dL in the context of other metabolic markers warrants attention, and levels above 100 mg/dL alongside low HDL should prompt a broader metabolic review. The triglyceride-to-HDL ratio is increasingly recognised as a practical proxy for insulin resistance when insulin testing is not available.
HDL Cholesterol (low HDL is a metabolic red flag, not just a heart one)
HDL below 50 mg/dL in women is one of the five criteria for metabolic syndrome, and it frequently tracks alongside insulin resistance because impaired insulin signalling disrupts the liver's ability to produce and clear lipoproteins efficiently. Estrogen normally supports HDL levels, so the drop in estrogen during menopause can cause HDL to fall even without changes in diet or lifestyle — making a low reading harder to interpret without context. When HDL is falling while triglycerides are rising, that combination is a stronger signal than either number in isolation.
High-Sensitivity C-Reactive Protein — hs-CRP (inflammation and insulin resistance are a two-way street)
Low-grade chronic inflammation both drives and is driven by insulin resistance, and hs-CRP is a sensitive marker of systemic inflammation that tends to rise as estrogen — which has anti-inflammatory properties — declines in menopause. An hs-CRP above 3 mg/L places women in a higher cardiovascular and metabolic risk category, and values even in the 1–3 mg/L range are worth tracking longitudinally. Elevated hs-CRP alongside other insulin resistance markers strengthens the overall picture and supports the case for earlier lifestyle intervention.
ALT (liver enzyme that quietly tracks fat accumulation)
Alanine aminotransferase (ALT) is a liver enzyme that rises when liver cells are under stress — and one of the earliest forms of that stress in insulin-resistant women is the accumulation of fat in the liver, known as metabolic-associated fatty liver disease (MAFLD). An ALT creeping above 25 U/L in women, even within the standard laboratory reference range, has been associated with increased metabolic and liver disease risk in research examining sex-specific thresholds. Because visceral fat accumulation accelerates in menopause and the liver is downstream of that process, ALT is a quietly informative marker that metabolic-aware clinicians are increasingly monitoring as part of a complete insulin resistance workup.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.